Treatment of anaerobic infections with lincomycin and clindamycin.
D000038:Abscess / Q000188:drug therapy; D000196:Actinomycosis / Q000188:drug therapy; D000693:Anaerobiosis; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D001439:Bacteroides / Q000187:drug effects; D002981:Clindamycin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D003016:Clostridium perfringens / Q000187:drug effects; D005673:Fusobacterium / Q000187:drug effects; D006801:Humans; D008034:Lincomycin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008100:Liver Abscess / Q000188:drug therapy; D008169:Lung Abscess / Q000188:drug therapy; D008297:Male; D008826:Microbial Sensitivity Tests; D010019:Osteomyelitis / Q000188:drug therapy; D010538:Peritonitis / Q000188:drug therapy; D011014:Pneumonia / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D014678:Veillonella / Q000187:drug effects; D014946:Wound Infection / Q000188:drug therapy
D002981:Clindamycin; D008034:Lincomycin